Enzymatic Kinetic Resolution of 2-Piperidineethanol for the Enantioselective Targeted and Diversity Oriented Synthesis †

Dario Perdicchia *, Michael S. Christodoulou, Gaia Fumagalli, Francesco Calogero, Cristina Marucci and Daniele Passarella *

Received: 2 November 2015; Accepted: 15 December 2015; Published: 24 December 2015

Dipartimento di Chimica, Università degli Studi di Milano, Via Golgi 19, 20133 Milano, Italy; michalis.christ@gmail.com (M.S.C.); gaia.fumagalli@unimi.it (G.F.); fcalogero87@gmail.com (F.C.); cristina.marucci@unimi.it (C.M.)
* Correspondences: dario.perdicchia@unimi.it (D.Pe.); daniele.passarella@unimi.it (D.Pa.);
† This paper is dedicated to the memory of Bruno Danieli, Professor of Organic Chemistry, Università degli Studi di Milano, 20122 Milano, Italy.

Abstract: 2-Piperidineethanol (1) and its corresponding N-protected aldehyde (2) were used for the synthesis of several natural and synthetic compounds. The existence of a stereocenter at position 2 of the piperidine skeleton and the presence of an easily-functionalized group, such as the alcohol, set 1 as a valuable starting material for enantioselective synthesis. Herein, are presented both synthetic and enzymatic methods for the resolution of the racemic 1, as well as an overview of synthesized natural products starting from the enantiopure 1.

Keywords: 2-piperidineethanol; piperidine alkaloids; enzymatic resolution; alkaloid synthesis

1. Introduction

2-Piperidineethanol (1) (Figure 1) is a chiral piperidine derivative bearing two functional group suitable for diversified elaborations of the molecule.

![Structure of 2-Piperidineethanol (1) and the corresponding N-protected aldehyde (2).](image)

Figure 1. Structure of 2-piperidineethanol (1) and the corresponding N-protected aldehyde (2).

With more than 10,000 molecules listed in SciFinder, contain the substructure of 2-piperidineethanol keeping the stereocentre in position 2 of piperidine, its potentiality is self-evident as a valuable chiral starting material in organic synthesis. In racemic form, it is a quite cheap compound since it is synthesized, on an industrial scale, by catalytic hydrogenation of 2-(2-hydroxyethyl)pyridine [1]; on the contrary, the enantiopure form is expensive and less available.

N-protected aldehyde (2), easily obtained by controlled oxidation of the parent alcohol, is the derivative of 2-piperidineethanol usually used to a great extent in synthesis.
The racemic compound is clearly related to the main exploitations but in the last decades there was a growing utilization of the enantiopure form, mostly concerning the synthesis of new leads in medicinal chemistry and the total synthesis of natural compounds.

Per se, it is utilized in the industrial plants for CO$_2$ capture [2]; as racemic starting compound was used in the synthesis of the catalysts for Ziegler–Natta polymerization [3]. It is used as scaffold for the synthesis of insect and mite repellents [4] as Icaridin (trade name Saltidin) [5]; tert-butyl carbamate (N-Boc) protected 2-piperidineethanol was patented as anthelmintic agents for humans and animals [6]. In medicinal chemistry, several leads were synthesized from racemic 1; it is worth citing the synthesis of a new orexin receptor antagonist [7], of a new class of non-opiate antinociceptive agents [8], of (aryloxyalkyl)piperidines as calcium channel antagonists [9] and of sulfonamide derivatives as 5-HT$_7$ receptor (5-hydroxytryptamine receptor 7) antagonists [10]. In some cases, a further improvement of activity was granted with the proper enantiomer, for example, the synthesis of aminooindane compounds as sodium channel inhibitors and TRPV1 receptor (transient receptor potential cation channel subfamily V member 1) activator for the treatment of pain [11], of a novel non-xanthine adenosine A1 receptor antagonist [12], of dermal anesthetic agents [13], of gonadotropin-releasing hormone antagonists [14], of a new inhibitor of cyclin-dependent kinases [15], of non-peptide quinolone GnRH (gonadotropin-releasing hormone) receptor antagonists [16] and of selective thrombin inhibitors [17].

Nature is the prime developer of compounds with a piperidine backbone with many structurally-interesting alkaloids; the wide range of biological activities in this family of natural products make them ideal targets for total synthesis. A selection of synthesis of alkaloids starting from enantiopure 1 is displayed at the end of this review.

2. Enantiopure 2-Piperidineethanol: Resolution versus Synthesis

Some research groups took into account the enantioselective synthesis of 1 or aldehyde 2; an early strategy was established on intermolecular nitron cycloadditions to chiral allyl ethers [18,19] obtaining benzyl carbamate (N-Cbz) 2. Asymmetric allylation was the next synthetic tool using a chiral auxiliary [20,21]; a synthetic sequence involving a Maruoka asymmetric allylation with a chiral catalyst [22] was successful in obtaining N-Boc 2. Recently, a straightforward organocatalyzed intramolecular aza-Michael reaction accomplished the synthesis of either N-Boc or N-Cbz 2 in high enantiomeric excess (e.e.) [23,24]. To obviate to the numerous synthetic steps necessary in the synthesis of 1 from scratch was also taken advantage of the homologation of the commercially-available N-(Boc)-5-pipeolic acid by carboxyl reduction, modified Swern oxidation, Wittig olefination, and enol ether acidic hydrolysis [25].

Resolution of the racemic mixture certainly provides practical benefits, considering the low price and good availability of 1, although suffers from the disadvantage that only half of the starting material is transformed into the desired product. Resolution can then offer the most cost efficient route to the enantiomerically pure chiral synthon. Indeed, it was the first method used to obtain the enantiopure isomer by careful recrystallization of the diastereoisomeric D-10-camphorsulfonate salt from ethanol-ether [26]. This method generally provided the alcohol in low yield, since there was a strong tendency for the racemic salt to separate, rather than the diastereoisomeric forms and numerous sequential recrystallizations were required to achieve enantiomeric excess of 95%. The procedure was subjected at slight modifications as it was repeated by several research groups and, although with some drawbacks, was used for the production of 12 kg of (R)-(−)-2-piperidineethanol [12]. Recently, the pushing necessity for a better resolving agent, brought about the development of two patents that utilized either N-sulphonyl pyroglutamic acid [27] or N-acetyl-l-leucine [28]: a single crystallization of the corresponding diastereoisomeric salt with 1, was enough to achieve high enantiomeric excess (86% and 95%, respectively) and higher with the second crystallization (99% and 98%, respectively).
Enantiopure 2-Piperidineethanol by Enzymatic Kinetic Resolutions

Enzymatic kinetic resolutions of racemates have been widely exploited in the past years for the preparation of enantiopure compounds [29–31]. Despite the breakthroughs achieved through the ability of enzymes to selectively react with only one of the enantiomers from a racemic mixture, there are only few examples reported for the resolution of 1, each one related to the reactivity at the hydroxyl group. It was a difficult task, due to the fact that the molecule is a conformationally flexible and primary alcohol located two carbons away from the molecule stereocenter. An early reference approached the resolution of several racemic piperidine derivatives [32] with either a stereocenter in position 2 or 3, exploiting the hydrolysis of an ester group by pig liver esterase (EC 3.1.1.1). With 1 two strategies were tested (Scheme 1) by the synthesis of esters 3 and 4:

\[
\begin{align*}
\text{3} & \rightarrow \text{1} \rightarrow \text{4}
\end{align*}
\]

Scheme 1. Synthesis of 2-piperidineethanol derivatives suitable for hydrolysis by pig liver esterase. iPr: isopropyl.

They were subjected to pig liver esterase hydrolysis at pH 7.0 to avoid the possibility of competing chemical hydrolysis or epimerization under the higher pH conditions; reactions were stopped after 50% conversion: results are reassumed in Scheme 2 showing a generally low enantioselectivity with up to 24% e.e. for acid (5).

\[
\begin{align*}
\text{3}(+) & \rightarrow \text{5}(-) \quad 40\% \text{ yield, 24}\% \text{ e.e.} \\
\text{4}(+/-) & \rightarrow \text{6}(-) \quad 45\% \text{ yield, 7}\% \text{ e.e.} \\
\text{4}(+) & \rightarrow \text{7}(-) \quad 41\% \text{ yield, 4}\% \text{ e.e.}
\end{align*}
\]

Scheme 2. Enzymatic kinetic resolutions of racemic 3 and 4. PLE: pig liver esterase; e.e.: enantiomeric excess.

In 1994, a first example of exploitation of the porcine pancreas lipase (PPL) for the resolution of 9-fluorenylethyl carbamate (N-Fmoc) 2-piperidineethanol (7) was reported in a Japanese patent [33]: vinyl acetate was used as the acylating agent and diisopropyl ether as solvent (Scheme 3) (in the English abstract are not indicated the e.e. of both the enantioenriched 8 and 7).

\[
\begin{align*}
\text{7}(+/-) & \rightarrow \text{8} \quad 74\% \text{ yield} \\
\text{7}(+/-) & \rightarrow \text{8} \quad 26\% \text{ yield}
\end{align*}
\]

Scheme 3. Enzymatic kinetic resolutions of racemic 7. PPL: porcine pancreas lipase. Fmoc: 9-fluorenylethyl carbamate.
Finally, in 2003, a comprehensive study on the enantioselective acylation of the residual primary alcohol (Scheme 4) by lipases was successfully realized [34]. A first screening of over 20 different lipase preparations was performed at 45 °C; an organic solvent (methyl tert-butyl ether) was selected as solvent as it is well-known that the enzymatic performances (activity and selectivity) can be enhanced greatly using organic solvents as a reaction medium, rather than their natural aqueous environments [35]; the protective groups of amino group tested were Boc, Cbz, and Fmoc.

This preliminary screening underlined that reaction enantioselectivities were generally quite low. The crude porcine pancreatic preparation possessed an opposite enantioselectivity compared to all the other lipases and Lipase PS was the more selective enzyme among the “(R)-lipases”. Comparing the three protective groups, N-Boc derivative was a slightly better substrate. A new screening was directed to pointing out the effect of different solvents for the reaction of N-Boc derivative catalyzed by Lipase PS and PPL: hexane was a slightly better solvent for the former while methyl tert-butyl ether remained the solvent of choice for the latter.

Finally, an optimized protocol was designed based on the observed complementary enantioselectivity of the two enzymes (Scheme 5). The racemic mixture 9 was acetylated under the best condition for Lipase PS; after that enzyme is filtered and reagent removed, the crude mixture was butanoylated by the PPL under the best condition for this enzyme. In this way, the low selectivity of the two lipases was enhanced. The final mixture, composed by enantioenriched acetate was acetylated under the best condition for Lipase PS; after that enzyme is filtered and reagent removed, the crude mixture 10, butanoate (S)-11 and the unreacted almost racemic 9, was easily purified by flash chromatography. Hydrolysis of the two esters was followed by a second step of acetylation on the two enantioenriched alcohols by the two lipases; after hydrolysis, both alcohols with high e.e. were obtained.

Scheme 5. Optimized protocol. (a) AcO=CH₂, hexane, 20 °C, 190 min (45%); (b) PrCOOCH=CH₂, MTBE, 20 °C, 11.5 h (30%), flash chromatography (AcOEt-hexane 1:9); (c) CH₃OH, Na₂CO₃; and (d) AcO=CH₂, MTBE, 20 °C, 46 h (48%). PPL: porcine pancreas lipase; PS: Lipase PS; Pr: propyl; Ac: acetyl; Boc: tert-butyl carbamate.
3. An Overview of the Synthetic Strategies in the Synthesis of Alkaloids Starting from Either Enantiopure 1 or 2

The development of suitable methods for accessing both enantiomers of 1 opened the path to the total synthesis of a wide range of natural compounds with high interest in medicinal chemistry; in an early stage, some of these syntheses were performed starting with racemic 1.

As previously mentioned, 2 is the main derivative of 2-piperidineethanol used in total synthesis where the stereogenic center at the C-2 position would readily encode the remaining stereochemical information into the final target. It is usually synthesized by Swern oxidation, but some troubles affect the recovery of the product and the scale up of the reaction. An enzymatic approach at the oxidation reaction of (R)-9 was realized by exploiting laccases [36], either from Trametes pubescens or from Myceliophthora termophyla, TEMPO (2,2,6,6-tetramethyl-1-piperidinyloxy) as a mediator, and molecular oxygen of the air as the primary oxidant (Scheme 6).

![Scheme 6. Oxidation reaction mediated by laccase. TEMPO: 2,2,6,6-tetramethyl-1-piperidinyloxy.](image)

3.1. Enantioselective Synthesis of the Alkaloid (+)-Aloperine

Aloperine (12) (Scheme 7) is a member of a small family of C_{15} alkaloids that is extracted from the seeds and leaves of Sophora alopecuroides, a shrub that grows in China and Russia, and later from Leptorhabdos parviflor Benth. Its pharmacological activity spreads between cardiovascular, anti-inflammatory, and anti-allergic features producing an intense synthetic interest in this molecule. In 2002, a synthesis of racemic 12 was realized [37]; the synthetic strategy (Scheme 7) relied on an efficient intermolecular Diels-Alder reaction as crucial step where derivative 15 was a key building block for the synthesis of the N-acylamidinoctane 14.

![Scheme 7. Retrosynthetic analysis of the synthesis of aloperine.](image)

In 2004, the corresponding enantioselective variant [36] was performed starting from (R)-9 for the synthesis of (R)-17 (Scheme 8); two consecutive enzymatic oxidations mediated by laccase were set for both the synthesis of aldehyde (R)-2 and ketone (R)-17.
Boehmeriasin A (22) is a phenanthroquinolizidine alkaloid extracted from *Boehmeria siamensis* Craib. It possesses a strong cytotoxic activity, more potent than taxol, against 12 cell lines from six panels of cancer including breast, kidney, prostate, colon, lung cancer, and leukemia, with topoisomerases and SIRT2 as involved targets. Recently, the synthesis of enantiopure 22 [38] was accomplished starting from aldehyde (S)-2 (Scheme 9).

The synthetic sequence begins with the Grignard addition to the enantiopure aldehyde (S)-2 followed by oxidation with DMP (Dess-Martin periodinane), deprotection of the Boc group, N-acylation of the amine, intramolecular aldol-type condensation, and palladium-catalyzed intramolecular coupling and reduction of the amide.

Recently, a quite similar synthetic strategy [39] was used for the synthesis of sulfonamide analogues of 22 as potent and orally active antitumor agents.
3.3. Enantioselective Synthesis of the Alkaloid Dumetorine

Dumetorine (28) is an alkaloid with piperidine structural unit that is extracted from the tubers of Dioscorea dumetorum Pax and used in folk medicine and arrow poisons. The enantioselective synthesis [40] was established on few key synthetic steps (Scheme 10) starting from the enantiopure aldehyde (S)-2. The second stereocenter was achieved by an asymmetric allylboration reaction with β-allyl-diisopinocamphenylborane, obtaining exclusively the required compound 23 (diastereoisomeric excess (de) > 95%). After acylation with acryloyl chloride, the dihydropyran ring was synthesized by ring-closing metathesis reaction with the second generation Grubbs catalyst. Unfortunately, the removal of the Boc group with TFA (trifluoroacetic acid) involved the formation of the byproduct 26, as the main component of the reaction mixture, and the desired free amine 27 in small amounts (10%). Finally, N-methylation was carried out by reductive amination with CH₂O in the presence of NaBH₃CN to give the target natural (+)-28.

![Scheme 10. Enantioselective synthesis of the alkaloid dumetorine.](image)

Recently, for the improvement of the synthesis, a sequence of five separate synthetic steps, was performed by flow chemistry technology with the advantages of minimal workup and purification [41]. Packed columns containing appropriate immobilized reagents or scavenger materials were used. The starting compound was the enantiopure alcohol (S)-9 that was converted into the corresponding aldehyde (S)-2 by continuously cycling the flow stream through a polymer-supported 2-iodoxybenzamide pre-packed column. In the second step, the insertion of the allyl group was realized by reaction with the Grignard reagent 2-methyl-allylmagnesium bromide; the two diastereoisomers, formed almost in 1:1 ratio, were purified on a silica gel cartridge to give the desired diastereoisomer 23. After acylation with acryloyl chloride, the ring-closing metathesis reaction was realized by a new PEG (polyethylene glycol)-supported Hoveyda catalyst working in homogeneous conditions ensured by the solubility of the catalyst in CH₂Cl₂, maintaining the possibility of simple catalyst recovery by solvent-promoted precipitation and filtration. The inherent instability of amine 27 was the main drawback of the early synthetic sequence (Scheme 10) since Michael addition of the secondary amine to the α,β-unsaturated lactone ring caused the formation of the byproduct 26 and significantly reduced the yield of the final reductive amination (39%). A definitive breakthrough was established by converting directly Boc protected 25 in final product 28 through an Eschweiler–Clarke reaction with formaldehyde in the presence of formic acid at high temperature: flash heating with a rapid warming to 140 °C gave a clean product with a yield of 92%.
3.4. Enantioselective Synthesis of the Alkaloids Sedamine, Allosedamine, Sedridines and Ethylnorlobelols

The structure of several alkaloids are easily recognized as derivatives of the reaction of 2 with an appropriate Grignard reagent. Indeed, starting from the enantiopure (S)-2, two diastereoisomeric alcohols 29 and 30 were generated (Scheme 11). Their Boc groups were easily converted into methyl groups by reduction with LiAlH₄ [34] affording, for R = Ph, respectively, (−)-allosedamine (31) and (−)-allosedidine (32); alternatively, 31 was synthesized from 29, through flow chemistry technology, by the protocol developed for the previously outlined Eschweiler–Clarke reaction [41].

![Scheme 11](image)

**Scheme 11.** Enantioselective synthesis of the alkaloids sedamine, allosedamine, sedridines, and ethylnorlobelols.

On the other hand, removing the Boc group from 29 and 30 afforded respectively (−)-allosedidine (33) and (+)-sedidine (34), for R = Me, (−)-2′-epi-ethylnorlobelol (35) and (+)-ethylnorlobelol (36), for R = Et [42].

3.5. Synthesis of the Enantiopure Alkaloids Coniine and Epidihydropinidine

Conine (38) is the major alkaloid extracted from *Conium maculatum* (poison hemlock) and responsible for its toxicity. It was synthesized from the enantiopure (S)-2 (Scheme 12) by elongating the chain at the 2-position of the piperidine ring through a Wittig reaction, hydrogenation of the double bond and removal of the Boc group [42].

![Scheme 12](image)

**Scheme 12.** Synthesis of the alkaloid (−)-coniine.
Closely related to coniine is the alkaloid epidihydropinidine (43) that shared the same synthetic steps for the building of the propyl group [40]. The key synthetic step was the Beak’s N-Boc-piperidine α-lithiation/alkylation methodology for the introduction of the methyl group at the C-6 position; TBDMS protection of the hydroxyl group of (R)-9 was important in order to keep the C-2 chain at a distance from the reactive center (Scheme 13). After deprotection and Dess–Martin oxidation to aldehyde 42, the synthesis proceeded alike Scheme 12.

Scheme 13. Enantioselective synthesis of the alkaloid (-)-epidihydropinidine. (a) imidazole, tert-butylimethylsilyl chloride (TBDMSCl); (b) N,N,N′,N′-Tetramethylethylenediamine (TMEDA), sec-BuLi, Et2O, −78 °C, MeSO4; (c) Na2CO3, MeOH; and (d) Dess-Martin reagent.

3.6. Enantioselective Synthesis of Polycyclic Piperidine Derivatives

The changeover of the aldehyde group of 2 into the carbon–carbon double bond of 37 allowed a switch of reactivity by exploiting reactions affecting the alkene group [43] such as intramolecular Heck reactions, 1,3-dipolar cycloadditions, ring closing metathesis and intramolecular chloroamination reactions, reaching an increased molecular complexity. Indeed, bicyclic derivative 45 was obtained by reaction of urea 44 using Pd(CH3CN)2Cl2 as a catalyst and CuCl2 as an oxidant (Scheme 14).

Scheme 14. Enantioselective synthesis of bicyclic derivative 45.

Combining more reactions together in order to modifying the carbon–carbon double bond before the 1,3-dipolar cycloaddition, allowed the stereoselective synthesis of fused tricyclic derivatives with up to three stereogenic centers. Then, aryl derivative 46 was subjected to an intramolecular Heck reaction (Scheme 15) obtaining the bicyclic alkene 47 that, after 1,3-dipolar cycloaddition, gave the tricyclic spiro derivative 48 as mixture of two diastereoisomers.
4. A General Overview of the Structures of Alkaloids Synthesized from both 1 or 2

Further examples of natural compounds synthesized starting from both enantiopure 1 or 2 are shortly exemplified in this subsection; the substructure derived from 1 is pointed out in red.

4.1. Enantioselective Synthesis of the Alkaloids (−)-Oncinotine, (−)-Isooncinotine, and (−)-Stellettamide B

(−)-Oncinotine (52) and (−)-Isooncinotine (53) (Figure 2) are a group of isomeric polyamine alkaloids which are characterized by macrocyclic lactams containing the biogenetic base spermidine; they are isolated from the stem bark of Oncinitis nitida (Apocynaceae). 52 was synthesized in 1996 [19] starting from N-Cbz 2 instead. 53 was synthesized in 2007 [44] from 1. Stellettamide B (54) (Figure 2) is extracted from a marine sponge of the genus Stelletta and showed antifungal and cytotoxic activity; it was synthesized in 2001 [20] from 1.
4.2. Enantioselective Synthesis of the Alkaloids (+)-Vertine and (+)-Lythrine

The azabicyclic skeleton of quinolizidine is a relevant structural subunit present in numerous alkaloids and can be built starting from 1. (+)-Vertine (55) and (+)-lythrine (56) are examples of this class of natural compounds (Figure 3); they are extracted from Decodon verticillatus and displayed a wide range of biological activities, such as anti-inflammatory, sedative, and antispasmodic actions; recently, was realized their total synthesis starting from 1 [45].

![Figure 3. Structures of the alkaloids (+)-vertine and (+)-lythrine.](image)

4.3. Enantioselective Synthesis of the Alkaloids (+)-Myrtine, (−)-Lupinine, and (+)-Epiepiquinamide

(+)-Myrtine (57), isolated from Vaccinium myrtillus, (−)-lupinine (58), isolated from the yellow lupin seeds (Lupinus luteus), as well as (+)-epiepiquinamide (59), isolated in 2003 from the poison frog Epipedobates tricolor, share a quite comparable structure, although they originate from different natural sources (Figure 4). They were synthesized in 2011 from N-Boc 2 [46].

![Figure 4. Structures of the alkaloids (+)-myrtine, (−)-lupinine, and (+)-epiepiquinamide.](image)

4.4. Enantioselective Synthesis of the Alkaloids (−)-Cermizine C, (−)-Senepodine G and (+)-Cermizine D

From the family of lycopodium alkaloids are worth to mention (−)-Cermizine C (60) and (+)-cermizine D (62), both isolated from the club moss Lycopodium cernuum and the related alkaloid (−)-senepodine G (61) from the club moss Lycopodium chinense (Figure 5); the second latter displaced modest cytotoxicity against murin lymphoma L1210 cells. 60 was synthesized from 61 by reduction with NaBH₄, while the synthesis of the latter was accomplished starting from 1 [47,48]. Enantioselective synthesis of 62 exploited the use of N-Boc 2 as common intermediate to access two of the three piperidine rings [49].

![Figure 5. Structures of the alkaloids (−)-cermizine C, (−)-senepodine G, and (+)-cermizine D.](image)
4.5. Enantioselective Synthesis of the Alkaloids Psylloborine A and Isopsylloborine A

The complex dimers psylloborine A (63) and isopsylloborine A (64) (Figure 6) belong to coccinellid family of alkaloids, materials secreted by numerous species of ladybugs as defensive compounds when provoked. In the synthesis, N-Boc 9 was identified as a common starting point for the two tricyclic intermediate of the dimerization reaction [50]; moreover, the synthetic strategy allowed the total syntheses of eight monomeric members of these class of alkaloids.

![Figure 6. Structures of the alkaloids psylloborine A and isopsylloborine A.](image)

4.6. Enantioselective Synthesis of the Alkaloids Tetraponerines T3, T4, T7, and T8

Tetraponerines are a family of alkaloids that Pseudomyrmecine ants of the genus Tetraponera segregate against their enemies; their structures possess a singular aminal moiety inside a fused tricycle. They act as paralyzing venoms since are efficient inhibitors of a range of nAChRs (nicotinic acetylcholine receptors). Recently, enantioselective synthesis of the tetraponerines T3 (65), T4 (66), T7 (67), and T8 (68) (Figure 7) was achieved starting from N-Cbz 2 [51,52]. Their anticancer activity, against four different carcinoma human cell lines was examined showing a promising cytotoxic activity of 67 against breast carcinoma cell line MCF-7.

![Figure 7. Structures of the tetraponerines T3, T4, T7, and T8.](image)

4.7. Enantioselective Synthesis of the Alkaloids (+)-Conhydrine and 4-(2-(Piperidin-2-yl)ethoxy)quinoline Derivatives

Other alkaloids that contain the piperidine unit are: (+)-conhydrine (69) (Figure 8) [53], which was isolated in 1856 from the seeds and leaves of the poisonous plant Conium maculatum L. and is effectively in the treatment of cognitive disorders since it has been shown to display memory-enhancing properties; and 4-(2-(piperidin-2-yl)ethoxy)quinoline derivatives (70), as selective agonists of somatostatin receptor subtype 2 (Figure 8) [54].

![Figure 8. Structure of (+)-conhydrine and general structure of 4-(2-(piperidin-2-yl)ethoxy)quinoline derivatives.](image)
5. Conclusions

The discovery of both synthetic and enzymatic methods for the obtaining of enantiopure 1 opens the way for the use of this compound as a vital starting material for the enantioselective synthesis of natural and synthetic compounds. This review highlights the synthesis of natural alkaloids starting from both enantiopure 2-piperidinediethanol and its corresponding derivative N-protected aldehyde 2.

Author Contributions: All authors contributed to the development of the overall structure and the writing of the manuscript.

Conflicts of Interest: The authors declare no conflict of interest.

References

1. Freifelder, M.; Robinson, R.M.; Stone, G.R. Hydrogenation of substituted pyridines with rhodium on carbon catalyst. J. Org. Chem. 1962, 27, 284–286. [CrossRef]
2. Paul, S.; Ghoshal, A.K.; Mandal, B. Absorption of carbon dioxide into aqueous solutions of 2-piperidinediethanol: kinetics analysis. Ind. Eng. Chem. Res. 2009, 48, 1414–1419. [CrossRef]
3. Zhang, L.; Fang, Y. Cyclic Organosilicon Compounds as Electron Donors in Ziegler-Natta Catalyst Systems for Producing Propylene Polymer Having High Melt-Flowability. PCT Int. Appl. Patent WO 2013063464, 2 May 2013.
4. Krueger, B.W.; Sasse, K.; Hoever, F.P.; Nentwig, G.; Behrenz, W. Preparation of α,ω-Amino Alcohols as Insect and Mite Repellents. Eur. Appl. Patent EP 289842, 9 November 1988.
5. He, H.; Zhao, D.; Zhu, Y. Process for Preparation of Insect Repellent Icaridin. Chinese Patent CN 102167681, 31 August 2011.
6. Harder, A.; von Samson-Himmelstjerna, G.; Krueger, B.W.; Mehlhorn, H.; Schmidt, J. Aminocarboxyloxy Compound Anthelmintic Agents for the Prevention of Parasitic Infections in Humans and Animals. PCT Int. Appl. Patent WO 200202115, 10 January 2002.
7. Gaillard, P.; Johnson, C.N.; Novelli, R.; Porter, R.A.; Stemp, G.; Thewlis, K.M. Preparation of N-Aroyl Cyclic Amines as Orexin Receptor Antagonists. PCT Int. Appl. Patent WO 2002089800, 14 November 2002.
8. Carson, J.R.; Carmosin, R.J.; Vaught, J.L.; Gardocki, J.F.; Costanzo, M.J.; Raffa, R.B.; Almond, H.R., Jr. 2-Substituted 1-azabicycloalkanes, a new class of non-opiate antinociceptive agents. J. Med. Chem. 1992, 35, 2855–2863. [CrossRef] [PubMed]
9. Brown, T.H.; Copper, D.G. Preparation of (Aryloxyalkyl)piperidines and Analogs as Calcium Channel Antagonists. PCT Int. Appl. Patent WO 9533723, 14 December 1995.
10. Forbes, I.T.; Rahman, S.K. Preparation of Sulfonamide Derivatives as 5-HT7 Receptor Antagonists. PCT Int. Appl. Patent WO 9749695, 31 December 1997.
11. Thompson, S.K.; Priestley, T.; Smith, R.A.; Saha, A.K.; Rudra, S.; Hajra, A.K.; Chatterjee, D.; Behrens, C.H.; He, Y.; Li, H.Y. Aminoindane Compounds as Sodium Channel Inhibitors and TRPV1 Receptor Activator and Their Preparation and Use in the Treatment of Pain. PCT Int. Appl. Patent WO 2012112969, 23 August 2012.
12. Zanka, A.; Uematsu, R.; Morinaga, Y.; Yasuda, H.; Yamazaki, H. Process development of a novel non-xanthine adenosine A1 receptor antagonist. Org. Process. Res. Dev. 1999, 3, 389–393. [CrossRef]
13. Aberg, G.; Chen, J.L. The R-Isomer of 2-[2-(N-(2-Indanyl)-N-phenylamino)ethyl]piperidine and Other Dermal Anesthetic Agents for Inducing Local Anesthesia, Analgesia and Sleep. PCT Int. Appl. Patent WO 2006037047, 6 April 2006.
14. Young, J.R.; Huang, S.X.; Chen, I.; Walsh, T.F.; de Vita, R.J.; Wyvrratt, M.J.; Goulet, M.T.; Ren, N.; Lo, J.; Yang, Y.T.; et al. Quinolones as gonadotropin releasing hormone (GnRH) antagonists: Simultaneous optimization of the C(3)-aryl and C(6)-substituents. Bioorg. Med. Chem. Lett. 2010, 10, 1723–1727. [CrossRef]
15. Paruch, K.; Dwyer, M.P.; Alvarez, C.; Brown, C.; Chan, T.Y.; Doll, R.J.; Keertikar, K.; Knutson, C.; Mckittrick, B.; Rivera, J.; et al. Discovery of Dinaciclib (SCH 727965): A potent and selective inhibitor of cyclin-dependent kinases. ACS Med. Chem. Lett. 2010, 1, 204–208. [CrossRef] [PubMed]
16. DeVita, R.J.; Goulet, M.T.; Wyvrratt, M.J.; Fisher, M.H.; Lo, J.L.; Yang, Y.T.; Cheng, K.; Smith, R.G. Investigation of the 4-O-alkylamine substituent of non-peptide quinolone GnRH receptor antagonists. Bioorg. Med. Chem. Lett. 1999, 9, 2621–2624. [CrossRef]
17. Danilewicz, J.C.; Abel, S.M.; Brown, A.D.; Fish, P.V.; Hawkeswood, E.; Holland, S.J.; James, K.; McElroy, A.B.; Overington, J.; Powling, M.J.; et al. Design of selective thrombin inhibitors based on the (R)-Phe-Pro-Arg sequence. *J. Med. Chem.* **2002**, *45*, 2432–2453. [CrossRef] [PubMed]

18. Ito, M.; Maeda, M.; Kibayashi, C. Diastereofacial selectivity in intermolecular nitrene cycloaditions to chiral allyl ethers. Application to chiral synthesis of conine. *Tetrahedron Lett.* **1992**, *33*, 3765–3768.

19. Ina, H.; Ito, M.; Kibayashi, C. Enantioselective Total synthesis of the macrocyclic spermidine alkaloid (−)-Oncinotide. *J. Org. Chem.* **1996**, *61*, 1023–1029. [CrossRef]

20. Yamazaki, N.; Dokoshi, W.; Kibayashi, C. Total synthesis of (−)-stellettamide b and determination of its absolute stereochemistry. *Org. Lett.* **2001**, *3*, 193–196. [CrossRef] [PubMed]

21. Bosque, I.; Gonzalez-Gomez, J.C.; Guijarro, A.; Foubelo, F.; Yus, M. Concise total synthesis and stereochemical analysis of Tetraponerines T3 and T4. *J. Org. Chem.* **2012**, *77*, 10340–10346. [CrossRef] [PubMed]

22. Satyalakshmi, G.; Suneel, K.; Shinde, D.B.; Das, B. Stereoselective total synthesis of the piperidine alkaloids, (+)-coniine, (+)-pseudoconhydrine, and (+)-sedamine through a common intermediate. *Tetrahedron Asymmetry* **2011**, *22*, 1000–1005. [CrossRef]

23. Carlson, E.C.; Rathbone, L.K.; Yang, H.; Collett, N.D.; Carter, R.G. Improved protocol for asymmetric, intramolecular heteroatom michael addition using organocatalysis: Enantioselective syntheses of homoproline, pelletierine, and homopipeolic acid. *J. Org. Chem.* **2008**, *73*, 5155–5158. [CrossRef] [PubMed]

24. Singh, R.; Panda, G. t-Proline derived nitrogenous steroidal systems: An asymmetric approach to 14-aza steroids. *RSC Adv.* **2013**, *3*, 19533–19544. [CrossRef]

25. Toy, M.S.; Price, C.C. d- and l-Polyconidine. *J. Am. Chem. Soc.* **1960**, *82*, 2613–2616. [CrossRef]

26. Toy, M.S.; Price, C.C. d- and l-Polyconidine. *J. Am. Chem. Soc.* **1960**, *82*, 2613–2616. [CrossRef]

27. Santaniello, E.; Ferraboschi, P.; Grisenti, P.; Manzocchi, A. The biocatalytic approach to the preparation of enantiomerically pure chiral building blocks. *Chem. Rev.* **1992**, *92*, 1071–1140. [CrossRef]

28. Toone, E.J.; Jones, J.B. Enzymes in organic synthesis. 40. Evaluation of the enantioselectivity of the pig liver esterase-catalyzed hydrolyses of racemic piperidine carboxylic acid esters. *Can. J. Chem.* **1987**, *65*, 2722–2726. [CrossRef]

29. Eguchi, T.; Mochida, K. Manufacture of Optically Active Piperidines with Lipase. Japanese Patent JP 06014798, 25 January 1994.

30. Angoli, M.; Barilli, A.; Lesma, G.; Passarella, D.; Riva, S.; Silvani, A.; Danielli, B. Remote stereocenter discrimination in the enzymatic resolution of piperidine-2-ethanol. short enantioselective synthesis of sedamine and allosedamine. *J. Org. Chem.* **2003**, *68*, 9525–9527. [CrossRef] [PubMed]

31. Santaniello, E.; Ferraboschi, P.; Grisenti, P.; Manzocchi, A. The biocatalytic approach to the preparation of enantiomerically pure chiral building blocks. *Chem. Rev.* **1992**, *92*, 1071–1140. [CrossRef]

32. Toone, E.J.; Jones, J.B. Enzymes in organic synthesis. 40. Evaluation of the enantioselectivity of the pig liver esterase-catalyzed hydrolyses of racemic piperidine carboxylic acid esters. *Can. J. Chem.* **1987**, *65*, 2722–2726. [CrossRef]

33. Eguchi, T.; Mochida, K. Manufacture of Optically Active Piperidines with Lipase. Japanese Patent JP 06014798, 25 January 1994.

34. Angoli, M.; Barilli, A.; Lesma, G.; Passarella, D.; Riva, S.; Silvani, A.; Danielli, B. Remote stereocenter discrimination in the enzymatic resolution of piperidine-2-ethanol. short enantioselective synthesis of sedamine and allosedamine. *J. Org. Chem.* **2003**, *68*, 9525–9527. [CrossRef] [PubMed]

35. Klibanov, A.M. Improving enzymes by using them in organic solvents. *Nature* **2001**, *409*, 241–246. [CrossRef] [PubMed]

36. Barilli, A.; Belinghieri, F.; Passarella, D.; Lesma, G.; Riva, S.; Silvani, A.; Danielli, B. Enzyme assisted enantioselective synthesis of the alkaloid (+)-aloperine. *Tetrahedron Asymmetry* **2004**, *15*, 2921–2925. [CrossRef]

37. Passarella, D.; Angoli, M.; Giordani, A.; Lesma, G.; Silvani, A.; Danielli, B. Concise total synthesis of (±)-aloperine and 6-epi-aloperine. *Org. Lett.* **2002**, *4*, 2925–2928. [CrossRef] [PubMed]

38. Chrístodoulou, M.S.; Calogero, F.; Baumann, M.; Garcia-Argaez, A.N.; Pieraccini, S.; Sironi, M.; Dapiaggi, F.; Bucci, R.; Broggini, G.; Gazzola, S.; et al. Boehmeriasin A as new lead compound for the inhibition of topoisomerasers and SIRT2. *Eur. J. Med. Chem.* **2015**, *92*, 766–775. [CrossRef] [PubMed]
39. Kwon, Y.; Song, J.; Lee, H.; Kim, E.-Y.; Lee, K.; Lee, S.K.; Kim, S. Design, synthesis, and biological activity of sulfonamide analogues of Antofine and Cryptopleurine as potent and orally active antitumor agents. *J. Med. Chem.* 2015, 58, 7749–7762. [CrossRef] [PubMed]

40. Passarella, D.; Riva, S.; Grieco, G.; Cavallio, F.; Checa, B.; Arioli, F.; Riva, E.; Comi, D.; Danieli, B. Enantiopure N-Boc piperidine-2-ethanol for the synthesis of (+)- and (−)-dumetorine, and (+)- and (−)-epidihydropinidine. *Tetrahedron Asymmetry* 2009, 20, 192–197. [CrossRef]

41. Riva, E.; Rencurosi, A.; Gagliardi, S.; Passarella, D.; Martinelli, M. Synthesis of (+)-Dumetorine and Congeners by Using Flow Chemistry Technologies. *Chem. Eur. J.* 2011, 17, 6221–6226. [CrossRef] [PubMed]

42. Passarella, D.; Barilli, A.; Belinghieri, F.; Fassi, P.; Riva, S.; Sacchetti, A.; Silvani, A.; Danieli, B. Short enantioselective synthesis of sedridines, ethylnorlobelols and conine via reagent-based differentiation. *Tetrahedron Asymmetry* 2005, 16, 2225–2229. [CrossRef]

43. Borsini, E.; Broggin, G.; Colombo, F.; Khansaa, M.; Fasana, A.; Galli, S.; Passarella, D.; Riva, E.; Riva, S. Enantiopure 2-piperidylacetaldehyde as a useful building block in the diversity-oriented synthesis of polycyclic piperidine derivatives. *Tetrahedron Asymmetry* 2011, 22, 264–269. [CrossRef]

44. Cheng, H.Y.; Hou, D.R. Efficient, asymmetric synthesis of (−)-iso oncinitone. *Tetrahedron* 2007, 63, 3000–3005. [CrossRef]

45. Chausset-Boissarie, L.; Arvai, R.; Cumming, G.R.; Guenee, L.; Kundig, E.P. Asymmetric synthesis of (+)-vertine and (+)-lythrine. *Org. Biomol. Chem.* 2012, 10, 6473–6479. [CrossRef] [PubMed]

46. Fustero, S.; Moscardo, J.; Sanchez-Rosello, M.; Flores, S.; Guerola, M.; del Pozo, C. Organocatalytic enantioselective synthesis of quinolizidine alkaloids (+)-myrtine, (−)-lupinine, and (+)-epiepiquinamide. *Tetrahedron* 2011, 67, 7412–7417. [CrossRef]

47. Snider, B.B.; Grabowski, J.F. Total synthesis of (−)-Senepodine G and (−)-Cermizine C. *J. Org. Chem.* 2007, 72, 1039–1042. [CrossRef] [PubMed]

48. Veerasamy, N.; Carlson, E.C.; Collett, N.D.; Saha, M.; Carter, R.G. Enantioselective approach to quinolizidines: Total synthesis of Cermizine D and formal syntheses of Senepodine G and Cermizine C. *J. Org. Chem.* 2013, 78, 4779–4800. [CrossRef] [PubMed]

49. Veerasamy, N.; Carlson, E.C.; Carter, R.G. Expedient enantioselective synthesis of Cermizine D. *Org. Lett.* 2012, 14, 1596–1599. [CrossRef] [PubMed]

50. Sherwood, T.C.; Trotta, A.H.; Snyder, S.A. A Strategy for complex dimer formation when biomimciry fails: Total synthesis of ten coccinellid alkaloids. *J. Am. Chem. Soc.* 2014, 136, 9743–9753. [CrossRef] [PubMed]

51. Bosque, I.; Gonzalez-Gomez, J.C.; Loza, M.I.; Brea, J. Natural tetraponerines: A general synthesis and antiproliferative activity. *J. Org. Chem.* 2014, 79, 3982–3991. [CrossRef] [PubMed]

52. Airiau, E.; Girard, N.; Pizzeti, M.; Salvadori, J.; Taddei, M.; Andrè, M. Hydroformylation of alkenylamines. Concise approaches toward piperidines, quinolizidines, and related alkaloids. *J. Org. Chem.* 2010, 75, 8670–8673. [CrossRef] [PubMed]

53. Shaikh, T.M.; Sudalai, A. Enantioselective synthesis of (−)-α-Conhydrine and (−)-Sedamine by L-Proline-Catalysed α-Aminoxygenation. *Eur. J. Org. Chem.* 2010, 3437–3444. [CrossRef]

54. Wolkenberg, S.E.; Zhao, Z.; Thut, C.; Maxwell, J.W.; McDonald, T.P.; Kinose, F.; Reilly, M.; Lindsley, C.W.; Hartman, G.D. Design, synthesis, and evaluation of novel 3,6-diaryl-4-aminoalkoxyquinolines as selective agonists of somatostatin receptor subtype 2. *J. Med. Chem.* 2011, 54, 2351–2358. [CrossRef] [PubMed]

© 2015 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons by Attribution (CC-BY) license (http://creativecommons.org/licenses/by/4.0/).